Convalescent therapy has been touted as a fast, effective response to Covid-19, but a new therapy by GigaGen Inc. could be even more promising.
Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill Covid-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as the company assesses the plasma-based treatment in a Phase III study.
LabCorp launched a new test that could assess the capacity of antibodies in patient plasma to inhibit the novel coronavirus.
CSL Behring is attempting to make a difference in the pandemic in various ways, including harnessing the power of antibodies from the blood of recovered COVID-19 patients.
A top U.S. scientist said governments should not count on a successful vaccine against COVID-19 being developed anytime soon when deciding whether to ease restrictions imposed to curb the pandemic.
The CoVIg-19 Plasma Alliance was founded to accelerate development of a plasma-derived hyperimmune globulin therapy against COVID-19.
As researchers and physicians try to identify ways to effectively treat and prevent COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, some are studying whether high-dose intravenous immunoglobulin (IVIg) could work. IVIg is a common blood plasma product that is used to treat other immune disorders.
A summary of daily biopharma industry news regarding the novel coronavirus trending on March 27, 2020, with the FDA now working with 220 test developers.
The same day that New York Gov. Andrew Cuomo announced the initiation of a clinical trial using blood plasma from patients who have recovered from COVID-19, the U.S. Food and Drug Administration announced wider support for the practice.
New York will launch a clinical trial using blood plasma from patients who have recovered from COVID-19, the disease caused by the novel coronavirus.
